The purpose of this clinical trial is to compare the use of an investigational medicine and lenalidomide vs. lenalidomide alone as maintenance in patients with newly diagnosed multiple myeloma who are minimal residual disease positive after an autologous stem cell transplant.
|Trial Phase||Phase 3|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
SparkCures is working closely with Janssen Research & Development to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors